Endometriosis News BioNews Texas

March 20th, 2014 at 5:00 AM

FDA Guidance Clears Way For Repros To Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex For Uterine Fibroids, Endometriosis

Back in November of 2013, BioNews Texas reported on how Woodlands-based Repros Therapeutics had received guidance from the United States Food and Drug Administration for its clinical trial on...

November 7th, 2013 at 5:34 AM

Repros Receives Guidance From FDA For Upcoming Proellex Clinical Study

Repros Therapeutics Inc. announced that it has received guidance from the FDA for its clinical trial on Proellex, a drug candidate for the treatment of uterine fibroids. The agency recommended...

June 18th, 2013 at 12:08 PM

Repros Therapeutics Inc. to offer up to 3,000,000 public shares of its common stock

In a press release issued yesterday, Repros Therapeutics, Inc., has announced that it will be offering up to three million shares of its common stock to the public. The offering to the public is...

BioNews-TX

News archive

FDA Guidance Clears Way For Repros To Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex For Uterine Fibroids, Endometriosis

Repros Receives Guidance From FDA For Upcoming Proellex Clinical Study

Repros Therapeutics Inc. to offer up to 3,000,000 public shares of its common stock